Psyence Biomedical announced that the first site initiation visit has been completed at the first Australian clinical trial site for the Company’s Phase IIb study of nature derived psilocybin as a potential treatment for Adjustment Disorder in the Palliative Care context. Psyence previously announced that it has entered into partnerships with Fluence and iNGENu CRO to support the study. In July, Psyence announced the successful export of the drug product, PEX010, to Australia, which marked a crucial step in preparation for initiation of the study. The affiliated trial site will soon commence screening patients, and the first subject is expected to be randomized into the study in October.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
- Psyence Biomedical signs term sheet for acquisition of Clairvoyant
- Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
- Psyence Biomedical Secures Psilocybin Licensing Deal
- Rising High: MINT Shango JV to acquire Cannabist’s Florida entity